Is Oxaliplatin Still the Oncology Gold Standard?
Oxaliplatin API,CAS 61825-94-3 supplier,Oxaliplatin bulk price 2026,Shaanxi Sunrise oncology supply,GMP certified cytotoxic intermediate,DMF registered Oxaliplatin,3-month CAPOX regimen R&D,Immunogenic Cell Death ICD oncology
Content
⚠ STRICT REGULATORY DIRECTIVE: B2B INDUSTRIAL SUPPLY ONLY
Shaanxi Sunrise Pharmaceutical Co., Ltd. operates strictly as an industrial wholesale manufacturer of active pharmaceutical ingredients. The technical analysis regarding Oxaliplatin (CAS: 61825-94-3) provided below is tailored exclusively for Formulation Scientists, R&D Directors, and Biopharma Procurement Managers. This product is a raw cytostatics intermediate intended solely for laboratory research and final dosage manufacturing scale-up. It is NOT a finished consumer drug and is strictly prohibited for direct personal therapeutic use.
Is Your Oxaliplatin Supply Ready for 2026 Volatility?
Introduction
Is Oxaliplatin still the gold standard in 2026? At Shaanxi Sunrise, we've seen the market narrative shift. This platinum-based cornerstone hasn't been sidelined by newer biologicals; instead, it has found a more complex and vital role in the current oncology landscape.
Between geopolitical trade shifts and a clinical push to reduce patient toxicity, sourcing Oxaliplatin in 2026 is no longer a simple bulk purchase. It’s now about securing API certainty and integrating with precision treatment models.
Supply Chain Volatility in 2026
The global market is currently dealing with structural supply issues that go beyond the usual cycles. We're seeing a real move toward consolidation in the API sector.
High-purity, GMP Certified APIs are increasingly concentrated among tier-one suppliers who can handle the soaring compliance costs and provide full DMF Documentation. For B2B procurement teams, the top priority has moved from chasing the lowest unit price to ensuring "supply resilience." In 2026, being able to guarantee stock in a volatile market is the real competitive edge.
The Clinical Shift: 3-Month vs. 6-Month Regimens
2026 clinical guidelines have fully embraced the IDEA consensus. The industry is moving away from the old "more is better" approach in favor of balancing efficacy with patient quality of life.
Reduced Toxicity: For low-risk cases, a 3-month CAPOX regimen is now the standard, significantly cutting down on long-term peripheral neuropathy.
Economic Efficiency: This shorter duration isn't just better for the patient; it optimizes clinic chair-time and lowers the overall burden on 2026 healthcare budgets.
Oxaliplatin’s Role in Modern Combination Therapy
Oxaliplatin is proving its worth in 2026 as a powerful "immune trigger." It doesn't just kill cancer cells; it induces Immunogenic Cell Death (ICD), which "tags" the tumor for the immune system to find.
This makes it an essential priming agent for the latest PD-1/PD-L1 inhibitors. By turning "cold" tumors into "hot" ones, Oxaliplatin remains the foundation of next-generation oncology protocols, even as Antibody-Drug Conjugates (ADCs) become more common.
Technical Specifications (Sunrise Standard)
| Parameter | Specification |
|---|---|
| Product Name | Oxaliplatin API |
| CAS Number | 61825-94-3 |
| Quality Standard | USP / EP / CP / JP Compliant |
| Purity (HPLC) | ≥99.5% |
| Documentation | GMP, DMF, COA, MSDS |
| Packaging | Customized Bulk Pharmaceutical Grades |
2026 Procurement FAQ: Oxaliplatin
Why is a Purity Threshold of ≥99.5% HPLC Mandated for Oxaliplatin API?
Ultra-high purity minimizes redundant plant matrix trace components and synthesis impurities. This guarantees exact formulation control and absolute batch-to-batch stability during premium solid-dose and injectable oncological manufacturing.
What are the Specific Storage Conditions and Shelf-Life Parameters?
We recommend storing the material in a cool, dry, and light-protected environment. Under original hermetically sealed pharmaceutical packaging, this API possesses a validated shelf-life of 24 months.
How Can We Request R&D Samples or Bulk Commercial Quotations?
We support R&D pilot evaluation starting at a 1kg minimum sample order, while commercial scale scale-up batches carry a standard MOQ of 25kg. Please utilize our inquiry interface to acquire up-to-date technical dossiers and commercial quote matrices.
Does Shaanxi Sunrise Provide Global Logistics and Customs Compliance Support?
Yes. Leveraging nearly two decades of international pharmaceutical export experience, we deliver exhaustive customs clearance documentation (including GMP, DMF, and specialized cytotoxic shipping declarations) to ensure swift global transit.
Regulatory Compliance and Application Statement
This product is strictly classified as an industrial-grade raw bulk substrate. It is supplied exclusively to qualified biopharma manufacturers for formulation scale-up or laboratory research, and carries no direct consumer medical or therapeutic claims.
Academic References:
1. Business Research Insights (2026): Global Oxaliplatin Forecasts.
2. The Lancet Oncology (2026): Adjuvant Chemotherapy Optimization in Colon Cancer.
3. USP 2026 Update: Managing Fragility in Global Oncology Supply Chains.
1. Business Research Insights (2026): Global Oxaliplatin Forecasts.
2. The Lancet Oncology (2026): Adjuvant Chemotherapy Optimization in Colon Cancer.
3. USP 2026 Update: Managing Fragility in Global Oncology Supply Chains.